+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Olaparib"

Prostate Cancer Drugs Market Report 2025 - Product Thumbnail Image

Prostate Cancer Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
From
Ovarian Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Ovarian Cancer Drugs - Global Strategic Business Report

  • Report
  • July 2025
  • 250 Pages
  • Global
From
From
From
HER2 Negative Breast Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

HER2 Negative Breast Cancer- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Advanced Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Advanced Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
Advanced Recurrent Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Advanced Recurrent Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Breast Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Breast Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Ovarian Cancer Pipeline Analysis Report - Product Thumbnail Image

Ovarian Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Breast Cancer Pipeline Analysis Report - Product Thumbnail Image

Breast Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Loading Indicator

Olaparib is a type of breast cancer drug used to treat advanced breast cancer in women with certain genetic mutations. It is a poly ADP-ribose polymerase (PARP) inhibitor, which works by blocking the action of an enzyme that helps cancer cells repair themselves. This makes it harder for the cancer cells to survive and grow. Olaparib is used in combination with other treatments, such as chemotherapy, to help slow the growth of cancer cells. It is also used to treat metastatic breast cancer, which is cancer that has spread to other parts of the body. Olaparib is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer in women with certain genetic mutations. It is also approved in the European Union and other countries. Some companies in the Olaparib market include AstraZeneca, Merck, Pfizer, and GlaxoSmithKline. These companies are involved in the research, development, and marketing of Olaparib and other breast cancer drugs. Show Less Read more